The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
CTC trial treating rare gynae cancer recruits first patients
13 May 2019
PEACOCC, a new gynaecological cancer study run by the CR UK & UCL Cancer Trials Centre and supported by Merck Sharp & Dohme Ltd, opened its first treating hospital site, UCLH, this February.

The trial will treat 48 women who have a rare type of gynaecological cancer (known as ‘clear cell cancer') with an immunotherapy drug called pembrolizumabThe women will have received standard chemotherapy treatment but their cancer has since come back or worsened. 

Clear cell cancer types make up for 15% gynaecological cancers diagnosed in women. Prognosis is poor following chemotherapy, leaving patients with limited or no further treatment options. 

PEACOCC is tackling the unmet need to answer whether treatment with pembrolizumab can provide better outcomes for these patients. Should the results be positive, this may lead to the licensing of pembrolizumab as a treatment for gynaecological clear cell cancer in the future. 

Laura Hughes, trial coordinator for PEACOCC at the CTC, remarked: ‘Thanks to all the hospital teams and groups involved in setting up the study, we at the CTC are pleased to have PEACOCC underway. The trial will hopefully answer key questions in improving the treatment options for patients who have this rare type of cancer.’

The study plans to open at four other oncology hospital units throughout the UK by the end of the Summer: Edinburgh Cancer Centre, Churchill Hospital in Oxford, the Christie in Manchester, and Mount Vernon Cancer Centre in Middlesex.

To find out more about the PEACOCC trial, please visit our trials page here.


Picture shows PEACOCC trial team at UCLH. 
From left to right: Barrington Gbadoe, Dr Rebecca Kristeleit, Dr Rowan Miller, Amy Smith, Waheeda Abida, Laura Tottenham, Sajida Adam, and Samantha Whinn
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us